MetaMed Medical SL, a consultancy specialised in commercialising new and innovative medical devices in Spain, Portugal and South America, will be attending the 13th Annual European Neuroendocrine Tumor Society taking place in Barcelona, Spain from the 9th to the 11th March.
MetaMed is commercial representative of Delcath Inc., the manufacturer of the Hepatic CHEMOSAT® Delivery System which is used for percutaneous intra-arterial administration of chemotherapeutic agent (melphalan hydrochloride) to the liver with subsequent extracorporeal filtration of the regional (hepatic) venous blood, lowering the concentration of chemotherapeutic agent in the blood before returning it to the systemic venous circulation. The concept of chemosaturation is to temporarily isolate the liver from the body's blood circulation and deliver concentrated doses of an anti-cancer drug directly to the liver, “saturating" the entire organ.
CHEMOSAT® has shown positive results in patients with Neuroendocrine Tumors with metastases in the liver. The treatment is available at leading cancer centres across Europe, including Hospital Sanchinarrio in Madrid and Clinica Rotger on Mallorca.
If you you would like to learn more about the Hepatic CHEMOSAT® Delivery System, please contact us to arrange a meeting either at the conference in Barcelona or your medical institution.
looking forward to improve
We are always happy to receive feedback. If you have any comments or suggestions let us know via the Contact Form under the Contact section.